MMI Raises €17M Series C+ for Robotic Microsurgery Platform

MMI (Medical Microinstruments) has raised €17 million in Series C+ funding, according to data on the company's financing history. The round was backed by the European Investment Bank and Angelini Ventures.

What MMI Does

MMI develops robotic solutions for microsurgery and super-microsurgery. Its core product, the Symani Surgical System, pairs what the company describes as the world's smallest articulated robotic micro-instruments with tremor-reduction and motion-scaling technology.

The system is designed to enable procedures on structures as small as 0.1 mm. According to the company, its indications span trauma and head-and-neck reconstruction, breast cancer surgery and lymphatic repair.

Founded in Italy in 2015, MMI manufactures the Symani Surgical System at its Pisa facility. The company states it was the first to have a robotic system of its kind approved by the FDA for reconstructive microsurgery in the United States.

The Round

• Round type: Series C+
• Amount: €17 million
• Investors: European Investment Bank, Angelini Ventures
• Announced: September 16, 2026

No lead investor was designated in the available data. The participation of the European Investment Bank, a European Union lending institution, alongside Angelini Ventures, a venture investor, gives the round a mix of institutional and strategic backing.

Why This Matters for the Microsurgery Segment

Microsurgery and super-microsurgery sit at the high-precision end of surgical robotics. The procedures require surgeons to manipulate vessels, nerves and lymphatic structures at a scale where human hand tremor becomes a limiting factor. Motion-scaling and tremor-reduction technology addresses that constraint directly, which is the premise behind the Symani platform.

The clinical areas MMI cites — trauma reconstruction, head-and-neck reconstruction, breast cancer surgery and lymphatic repair — are all fields where reconstructive microsurgical techniques are established but technically demanding. A robotic platform that lowers the skill barrier or improves consistency in these procedures addresses a real clinical need rather than a speculative one.

Regulatory Position

The company's FDA approval for reconstructive microsurgery in the US is a notable milestone. Regulatory clearance in this category is not trivial, and being first to market with a robotic system of this kind creates a defensible position. It also means MMI is past the pure development stage and into commercialization and clinical adoption.

Manufacturing and Scale

MMI manufactures at its Pisa facility, keeping production in-house. For a company building instruments that operate at 0.1 mm scale, controlling manufacturing tolerances is likely central to product performance and reliability. Vertical integration at this level of precision is a meaningful operational asset.

What to Watch

With a Series C+ round, MMI is extending its capitalization beyond the initial Series C rather than raising a new priced round at a different stage. The capital is likely directed toward commercial expansion, clinical adoption and continued manufacturing scale-up.

For observers of the surgical robotics market, MMI occupies a distinct niche. Most surgical robotics activity concentrates on general surgery, orthopedics or endoscopy. Microsurgery and super-microsurgery remain comparatively underserved by robotic platforms, which is precisely where MMI has staked its position.

The combination of FDA approval, in-house manufacturing and a focused clinical indication set gives MMI a clear profile. This round adds capital to push that profile into broader clinical use.